Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC

Inclusion criteria

• ✓. Routine blood test results meet the criteria (no blood transfusion or use of blood products, and no use of G-CSF or other hematopoietic stimulating factors within 14 days)
• ✓. HB≥90 g/L
• ✓. ANC≥15×10\^9/L
• ✓. PLT≥80×10\^9/L
• ✓. The following criteria should be met in the biochemical tests:
• ✓. TBIL\<1.5×ULN
• ✓. ALT and AST\<2.5×ULN;for patients with liver metastasis, ALT and AST \>5×ULN
• ✓. Serum Cr≤1.25×ULN or Endogenous creatinine clearance rate\>45 ml/min (Cockcroft-Gault formula)